Presentations: Leipzig Interventional Course – interdisciplinary global platform for endovascular interventions

Room 1 - Main Arena 1

21 events

Tuesday, January 28th: 8:00 - 9:30, Room 1 - Main Arena 1

Symposium: Stepping forward: Changing the standard of care in lower limb treatments

supported with an educational grant from Abbott Vascular

Moderator:

Dierk Scheinert

Panel:

Luis Palena, Yann Gouëffic, Koen Deloose, Erwin Blessing
1. 08:00 - 08:05
  
  Welcome
2. 08:05 - 08:13
  
  Mimetic stent technology – providing safe, sustained, and optimal care
3. 08:13 - 08:38
  
  Live case transmission from Leipzig
4. 08:38 - 08:46
  
  Supersub II – preliminary results
5. 08:46 - 08:54
  
  STELLA Supera – 12-month results revealed
6. 08:54 - 09:19
  
  Live case transmission from Leipzig
7. 09:19 - 09:27
  
  Supera VMI-CFA study – 2-year follow-up, ready to change the standard of care?
8. 09:27 - 09:30
  
  Discussion and conclusion
Tuesday, January 28th: 9:30 - 11:00, Room 1 - Main Arena 1

Latest insights on safety and efficacy of drug-coated devices

Moderator:

Dierk Scheinert, William Gray

Panel:

Hiroyoshi Yokoi, Andrew Holden, Marianne Brodmann, Peter Schneider, Thomas Zeller, Eva Freisinger
1. FOCUS ON PACLITAXEL SAFETY
2. 09:30 - 09:40
  
  The controversy about Paclitaxel safety – where do we stand? A summary of concerns, available data, and open questions
3. 09:40 - 09:45
  
  FIRST TIME DATA RELEASE: In depth independent safety analysis by Syntactx (CRO) of the Lutonix SFA DCB
4. 09:45 - 09:50
  
  FIRST TIME DATA RELEASE: Paclitaxel exposure and dosage of drug-coated balloons for the treatment of PAD: Exploring mortality rates by regions around the globe
5. 09:50 - 09:55
  
  New long-term information on PTX coated DCB: 5-year results from the AcoArt study
6. 09:55 - 10:00
  
  Latest information on long-term efficacy and safety on the Zilver PTX programme
7. 10:00 - 10:05
  
  Mortality after use of Paclitaxel-based devices in peripheral arteries: A real-world safety analysis
8. 10:05 - 10:12
  
  The presence and the future of drug-coated devices: What to expect in the next 5 years?
9. 10:12 - 10:17
  
  Panel discussion
10. FOCUS ON NEW EFFICACY DATA AND NEW APPROACHES
11. 10:17 - 10:22
  
  FIRST TIME DATA RELEASE: COMPARE-RCT of low dose vs. high dose Paclitaxel coated balloons: 1-year results of the full cohort
12. 10:22 - 10:27
  
  FIRST TIME DATA RELEASE: 6-month results from Lutonix SFA Japan PMS update
13. 10:27 - 10:32
  
  FIRST TIME DATA RELEASE: Illumenate 4-year update
14. 10:32 - 10:37
  
  Drug-coated balloon angioplasty of femoropopliteal lesions maintained superiority over standard balloon – 2-year results of the randomized EffPac trial
15. 10:37 - 10:42
  
  RANGER II SFA: Randomized trial of RANGER DCB vs. PTA in the SFA
16. 10:42 - 10:47
  
  The DCB dose difference: A comparison of drug in tissues of different .018 DCBs
17. 10:47 - 10:52
  
  Post-DCB dissection repair: 12-month results from TOBA III
18. 10:52 - 11:00
  
  Discussion and conclusion
Tuesday, January 28th: 11:00 - 12:30, Room 1 - Main Arena 1

Symposium: Advanced techniques for the treatment of CLI patients

supported with an educational grant from Philips

Moderator:

Marco Manzi, Jihad Mustapha

Panel:

Konstantinos Stavroulakis, Michael Lichtenberg, Roberto Ferraresi
1. 11:00 - 11:06
  
  The role of advanced imaging in CLI
2. 11:06 - 11:26
  
  Live case transmission from Leipzig
3. 11:26 - 11:32
  
  The role of vessel prep in CLI
4. 11:32 - 11:52
  
  Live case transmission from Bergamo
5. 11:52 - 11:58
  
  DCB in CLI: Rationale and benefit in current times
6. 11:58 - 12:30
  
  Discussion and conclusion
Tuesday, January 28th: 12:30 - 13:25, Room 1 - Main Arena 1

Lunch symposium: Paclitaxel and your practice: Global perspectives

supported with an educational grant from COOK Medical

Moderator:

William Gray

Panel:

Thomas Zeller, Osamu Iida, Robert Morgan, Iris Baumgartner
1. 12:30 - 12:32
  
  Introduction
2. 12:32 - 12:42
  
  How Paclitaxel is perceived in Japan
3. 12:42 - 12:52
  
  Impact of society guidelines in my daily practice
4. 12:52 - 13:02
  
  Applying the guidelines to my treatment algorithm
5. 13:02 - 13:12
  
  Follow the data: Zilver PTX global data analysis
6. 13:12 - 13:17
  
  Overcoming the meta-analysis: Moving forward
7. 13:17 - 13:25
  
  Summary of symposium, discussion, and debate
Tuesday, January 28th: 13:30 - 15:00, Room 1 - Main Arena 1

Symposium: Optimizing revascularisation in patients with risk factors and complex peripheral arterial lesions

sponsored by Medtronic

Moderator:

Dierk Scheinert, Thomas Zeller

Panel:

Andrew Holden, Giovanni Torsello
1. 13:30 - 13:35
  
  Introduction
2. 13:35 - 13:43
  
  Is there a durable treatment option for challenging lesions? the scientific evidence for drug-coated balloons
3. 13:43 - 13:51
  
  Anatomically challenging lesion locations: What are my treatment options?
4. 13:51 - 14:16
  
  Live case transmission from Bergamo
5. 14:16 - 14:24
  
  Opening your BTK treatment options: Unique tools & techniques
6. 14:24 - 14:49
  
  Live case transmission from Leipzig
7. 14:49 - 15:00
  
  Panel discussion and conclusion
Tuesday, January 28th: 15:00 - 16:30, Room 1 - Main Arena 1

Symposium: AcoArt drug eluting solutions: 5 years safety and effectiveness in FP, latest outcome in BTK

supported with an educational grant from Acotec

Moderator:

Dierk Scheinert, Xin Jia

Panel:

Zhidong Ye, Guanhua Xue, Jun Cheng, Weihao Shi, Wei Wang
1. 15:00 - 15:09
  
  The application of DCB in Type C/D lesion
2. 15:09 - 15:18
  
  Redefining DCB in BTK treatment: 12-month outcomes of AcoArt II study
3. 15:18 - 15:27
  
  Why DCBs should be first line therapy for most femoropopliteal lesions
4. 15:27 - 15:36
  
  DCB in BTK: 12-month results of AcoArt BTK Italy study
5. 15:36 - 15:45
  
  Exploring DCB in TAO
6. 15:45 - 15:54
  
  Distal embolization after DCB – true or false?
7. 15:54 - 16:03
  
  Preliminary experience of using DCB in new indications
8. 16:03 - 16:20
  
  Live case transmission from Leipzig
9. 16:20 - 16:30
  
  Discussion and conclusion
Tuesday, January 28th: 16:30 - 18:00, Room 1 - Main Arena 1

New stent technologies and advanced concepts for implantable vascular scaffolds

Moderator:

William Gray, Koen Deloose

Panel:

Klaus Amendt, Brian DeRubertis, Yann Gouëffic, Osamu Iida
1. 16:30 - 16:37
  
  2-year outcomes from the IMPERIAL randomized study of Eluvia and Zilver PTX
2. 16:37 - 16:42
  
  BATTLE: A RCT comparing bare metal stent vs. Paclitaxel polymer free eluting stent: 2-year outcomes
3. 16:42 - 16:47
  
  ILLUMINA study – 2-year results with a polymer free Sirolimus eluting DES in femoropopliteal arteries
4. 16:47 - 16:52
  
  VaibAhn steNt graft placement for superficial femoral artery disease reQUIring endovaScular tHerapy: Vanquish study
5. 16:52 - 16:57
  
  Increased outward force of self-expanding BMS in the SFA could be a significant risk factor for a restenosis
6. 16:57 - 17:02
  
  Difference in clinical outcomes of low COF stent vs. high COF stent proven in clinical practice
7. 17:02 - 17:22
  
  Live case transmission from Berlin
8. 17:22 - 17:27
  
  FIRST TIME DATA RELEASE: Final results from the LOCOMOTIVE registry using the VascuFlex Multi-LOC stent system in real-world lesions
9. 17:27 - 17:32
  
  TINTIN study: Final 12–month data with the combination of Luminor DCB+SX stent in TASC C and D lesions
10. 17:32 - 17:37
  
  A single-center experience with the Tack endovascular system: Real-world tacking above and below-the-knee
11. 17:37 - 17:42
  
  Dissecting the TOBA data above and below-the-knee: What it means in practice
12. 17:42 - 17:47
  
  Latest updates from the MIMICS clinical programme: Studying BioMimics 3D – The Swirling Flow Stent
13. 17:47 - 17:52
  
  1-year results in unselected, real-world patients with the BioMimics 3D Swirling Flow stent in femoropopliteal lesions: The MIMICS-3D Registry
14. 17:52 - 17:57
  
  Endoluminal bypass in CLI patient: Long term results
15. 17:57 - 18:00
  
  Discussion and conclusion
Wednesday, January 29th: 8:00 - 9:30, Room 1 - Main Arena 1

Optimizing the treatment of BTK vessels in critical limb ischemia

Moderator:

Dierk Scheinert, Peter Schneider

Panel:

Dai-Do Do, Francesco Liistro, Matthew Menard, Luis Palena, Jihad Mustapha, Steven Kum
1. 08:00 - 08:05
  
  FIRST TIME DATA RELEASE: Latest 24-month BTK global real-world registry Lutonix DCB outcomes
2. 08:05 - 08:10
  
  FIRST TIME DATA RELEASE: Update on BTK IDE Lutonix DCB – complex patient subset
3. 08:10 - 08:15
  
  FIRST TIME DATA RELEASE: Stellarex in the real-world: Interim look at the BTK cohort
4. 08:15 - 08:20
  
  12-month results from the randomized AcoArt BTK study
5. 08:20 - 08:25
  
  Initial experience with the temporary drug-coated Spur system to enhance drug delivery to the vessel wall
6. 08:25 - 08:30
  
  Small artery disease (SAD) and media artery calcification (MAC) are changing the fate of CLI patients
7. 08:30 - 08:35
  
  FIRST TIME DATA RELEASE: LimFlow pDVA for no-option CLTI: The ALPS registry data at 2 years
8. 08:35 - 08:55
  
  Live case transmission from Leipzig
9. 08:55 - 09:00
  
  Optimizing below-the-knee angioplasty: Dissections matter
10. 09:00 - 09:05
  
  Repairing BTK dissection: Results from the TOBA II BTK pivotal study
11. 09:05 - 09:10
  
  Intra-procedural extra-vascular ultrasound prevents early and late failures in BTK
12. 09:10 - 09:15
  
  High pressure non compliant POBA in real-world CLI – 12-month results from the JADE registry in Singapore
13. 09:15 - 09:20
  
  The advantages of using perfusion angiography during CLI procedures
14. 09:20 - 09:25
  
  Tissue perfusion assessment drives and predicts clinical success in severe CLI: experience from a 330 patient study
15. 09:25 - 09:30
  
  Discussion and conclusion
Wednesday, January 29th: 9:30 - 11:00, Room 1 - Main Arena 1

Symposium: Drug eluting technologies for PAD: From fundamentals to future

supported with an educational grant from Boston Scientific

Moderator:

Dierk Scheinert, Thomas Zeller

Panel:

Ravish Sachar, Marianne Brodmann, Andrew Holden, Giovanni Torsello
1. 09:30 - 09:32
  
  Introduction
2. 09:32 - 09:42
  
  Fundamentals of drug coated balloons
3. 09:42 - 09:52
  
  Lessons from Ranger SFA II RCT (Ranger DCB vs. PTA)
4. 09:52 - 10:02
  
  Lessons from COMPARE RCT (Ranger DCB vs. IN.PACT DCB)
5. 10:02 - 10:27
  
  Live case transmission from Leipzig
6. 10:27 - 10:37
  
  Fundamentals of drug eluting stents
7. 10:37 - 10:47
  
  Lessons from IMPERIAL RCT (Eluvia DES vs. Zilver PTX)
8. 10:47 - 10:57
  
  Future trials with drug eluting technologies
9. 10:57 - 11:00
  
  Close and key take aways
Wednesday, January 29th: 11:00 - 12:30, Room 1 - Main Arena 1

Symposium: Approaches for fem-pop complex disease: What is the best option? Experts share treatment decisions and their cases

supported with an educational grant from Gore & Associates

Moderator:

Peter Soukas

Panel:

Michel Reijnen, Markus Steinbauer, Jorge Fernández Noya, Jose Antonio del Castro
1. 11:00 - 11:10
  
  The physician algorithm for treatment of fem-pop occlusive disease
2. 11:10 - 11:25
  
  Live case transmission from Paris
3. 11:25 - 11:35
  
  Treatment choice in complex SFA lesions
4. 11:35 - 11:45
  
  Endovascular first: When this is the appropriate choice?
5. 11:45 - 11:55
  
  GORE® VIABAHN® endoprosthesis in complex SFA lesions
6. 11:55 - 12:05
  
  Value of covered stents in fem-pop disease
7. 12:05 - 12:20
  
  Recorded case presentation
8. 12:20 - 12:30
  
  Discussion and conclusion
Wednesday, January 29th: 12:35 - 13:25, Room 1 - Main Arena 1

Lunch symposium: The latest in clinically proven technologies to treat complex PAD and venous diseases

sponsored by BD

Moderator:

Eric Ducasse

Panel:

Miguel Montero-Baker, Patrick Geraghty
1. 12:35 - 12:41
  
  How low pressure inflation with scoring technologies better preserves the vessel and increases revascularisation success
2. 12:41 - 12:47
  
  The UltraScore™ Scoring Ballon: Update of a multi-center registry
3. 12:47 - 12:53
  
  Update on the Lutonix® Drug Coated Balloon IDE trial with below-the-knee disease
4. 12:53 - 12:59
  
  FIRST TIME DATA RELEASE: The IDE below-the-knee Japan cohort
5. 12:59 - 13:05
  
  What we know about the paclitaxel-related mortality in femoro-popliteal arteries, and how it impacts my practice
6. 13:05 - 13:11
  
  Lutonix™ Drug Coated Balloon clinical program overview and published independent safety analysis results
7. 13:11 - 13:19
  
  Panel discussion
8. 13:19 - 13:25
  
  VENOVO® Arnsberg registry 24-month results
Wednesday, January 29th: 13:30 - 15:00, Room 1 - Main Arena 1

Symposium: Redefining treatment strategy with new generation Sirolimus coated balloon for peripheral vascular disease with nanolute technology

supported with an educational grant from Concept Medical

Moderator:

Sahil Parikh

Panel:

Thomas Zeller, Dierk Scheinert, Jos van den Berg, Sameer Dani
1. 13:30 - 13:36
  
  The role of Sirolimus coated balloon in peripheral vascular disease
2. 13:36 - 13:42
  
  The Magic Touch – PTA Sirolimus coated balloon – insights from pre-clinical evaluation
3. 13:42 - 13:51
  
  XTOSI: MagicTouch sirolimus coated balloon for PAD and FUTURE SFA/FUTURE BTK randomised controlled trials
4. 13:51 - 14:11
  
  Live case transmission from Jena
5. 14:11 - 14:16
  
  Discussion on case
6. 14:16 - 14:36
  
  Live case transmission from Leipzig
7. 14:36 - 14:41
  
  Discussion on case
8. 14:41 - 14:48
  
  Outcomes of Sirolimus coated angioplasty balloon in the treatment of dysfunctional AVF and AVG
9. 14:48 - 14:53
  
  SIRONA – head to head comparison of Sirolimus vs. Paclitaxel drug eluting balloon for femoral popliteal artery
10. 14:53 - 15:00
  
  Discussion and conclusion
Wednesday, January 29th: 15:00 - 16:30, Room 1 - Main Arena 1

VIVA@LINC: Atherectomy as adjunctive or definitive therapy: What’s the data and what are the techniques?

Moderator:

John Rundback, Peter Schneider

Panel:

Daniela Branzan, Steven Kum, Theodosios Bisdas, Lawrence Garcia
1. 15:00 - 15:05
  
  Announcement of the winners of the Vascular Carreer Award 2020 – Steven Kum and Parag Patel
2. 15:05 - 15:30
  
  Live case transmission from Kingsport
3. 15:30 - 15:38
  
  Indications and lesion selection for femoral-popliteal atherectomy
4. 15:38 - 15:46
  
  Tools, techniques, and tips for safe and successful atherectomy below-the-knee
5. 15:46 - 15:54
  
  Atherectomy and anti-restenotic therapy: What do we know so far and what are the likely next developments?
6. 15:54 - 16:02
  
  Complications of atherectomy and how to manage them
7. 16:02 - 16:27
  
  Live case transmission from Kingsport
8. 16:27 - 16:30
  
  Discussion and conclusion
Wednesday, January 29th: 16:30 - 18:00, Room 1 - Main Arena 1

Advanced techniques for complex femoropopliteal lesions

Moderator:

Thomas Zeller, George Adams

Panel:

Kazushi Urasawa, Brian DeRubertis, Peter Soukas, Torsten Fuß, Martin Werner, Lawrence Garcia
1. 16:30 - 16:35
  
  When, where, and how: An update on the support catheters
2. 16:35 - 16:41
  
  Step-by-step approach in CTOs and the need for retrograde approaches
3. 16:41 - 17:01
  
  Live case transmission from Leipzig
4. 17:01 - 17:06
  
  FIRST TIME DATA RELEASE: Advancing laser therapy: Different setting for different lesions
5. 17:06 - 17:11
  
  Benefit of lesion preparation with a rotational atherectomy device – mid-term outcomes
6. 17:11 - 17:16
  
  The future of scoring PTA & update of a multi-center registry ATK/BTK
7. 17:16 - 17:21
  
  FIRST TIME DATA RELEASE: IN.PACT global study 150mm cohort: Outcomes through 3 years
8. 17:21 - 17:26
  
  FIRST TIME DATA RELEASE: Drug-coated balloon outcomes in the femoropopliteal by vessel size
9. 17:26 - 17:46
  
  Live case transmission from Kingsport
10. 17:46 - 17:51
  
  Vessel preparation in calcified lesions: Which method for which lesion?
11. 17:51 - 18:00
  
  Discussion and conclusion
Thursday, January 30th: 8:00 - 9:30, Room 1 - Main Arena 1

The last frontiers: Extreme BTK interventions for limb salvage in CLI

Moderator:

Roberto Ferraresi, Steven Kum

Panel:

Dai-Do Do, Jihad Mustapha, Hiroyoshi Yokoi, Michael Edmonds, Francesco Liistro, Jim A. Reekers
1. 08:00 - 08:20
  
  Live case transmission from Abano Terme
2. 08:20 - 08:26
  
  Peripheral vascular morbidity and its treatment in diabetic patients with renal failure
3. 08:26 - 08:32
  
  How to guide your intervention with perfusion angiography
4. 08:32 - 08:38
  
  Advantages of intra-vascular imaging in BTK procedures
5. 08:38 - 08:43
  
  Drug-coated balloon angioplasty of infrapopliteal lesions in patients with critical limb ischaemia: 1-year results of the APOLLO trial
6. 08:43 - 08:49
  
  When is below-the-ankle angioplasty indicated?
7. 08:49 - 09:09
  
  Live case transmission from Leipzig
8. 09:09 - 09:14
  
  5-year results from the ABSORB BTK study: Bioresorbable scaffolds for the treatment of tibial artery stenosis
9. 09:14 - 09:19
  
  Latest experience with the 3F Microstent in complex BTK procedures
10. 09:19 - 09:30
  
  Discussion and conclusion
Thursday, January 30th: 9:30 - 11:00, Room 1 - Main Arena 1

Symposium: Rotarex®S in ISR and bypass occlusion: Are they still only a niche indication?

supported with an educational grant from Straub Medical

Moderator:

Romaric Loffroy

Panel:

Bruno Freitas, Bruno Migliara, Christos Rammos
1. 09:30 - 09:40
  
  Rotarex®S for in-stent stenosis/occlusion: A French multicentre experience with 128 patients
2. 09:40 - 10:05
  
  Live case transmission from Leipzig
3. 10:05 - 10:15
  
  Rotarex®S for in-stent restenosis/occlusion: The Leipzig experience with more than 300 patients
4. 10:15 - 10:40
  
  Live case transmission from Leipzig
5. 10:40 - 10:50
  
  Clinical and cost effectiveness of treating bypass occlusion with Rotarex®S vs. surgery
6. 10:50 - 11:00
  
  SAVioR trial: Acute improvement of vascular function following debulking atherectomy with Rotarex®S
Thursday, January 30th: 11:00 - 12:30, Room 1 - Main Arena 1

Innovating dialysis access: Latest data and developments in creation, maintenance, and program implementation

sponsored by BD

Moderator:

Dierk Scheinert

Panel:

Nicholas Inston, Panagiotis Kitrou, Eric Ducasse, Tobias Steinke, Ounali Jaffer
1. 11:00 - 11:07
  
  The WavelinQ EndoAVF™ system: Past, present, future
2. 11:07 - 11:17
  
  Recorded case presentation: Procedure with the EndoAVF 4F™ system
3. 11:17 - 11:22
  
  The 1st French experience with the WavelinQ EndoAVF 4F™ system
4. 11:22 - 11:27
  
  EndoAVF secondary interventions
5. 11:27 - 11:37
  
  Panel discussion
6. 11:37 - 11:44
  
  The Covera™ Vascular Covered stent in fistula: the AVEVA & AVENEW studies
7. 11:44 - 11:54
  
  Recorded case presentations with Covera™ Vascular Covered stent
8. 11:54 - 12:04
  
  Panel discussion
9. 12:04 - 12:09
  
  DCB in central venous stenosis. A multicenter retrospective study
10. 12:09 - 12:15
  
  An overview of the Lutonix® Drug Coated Balloons clinical program and patient population characteristics
11. 12:15 - 12:20
  
  Use of drug-coated balloons in dysfunctional arteriovenous dialysis access treatment: The effect of consecutive treatments on lesion patency
12. 12:20 - 12:30
  
  Panel discussion
Thursday, January 30th: 12:30 - 13:30, Room 1 - Main Arena 1

Focus session: Percutaneous bypass technique for challenging femoropopliteal occlusions

Moderator:

Peter Schneider

Panel:

Dierk Scheinert, Kenneth Ouriel, Sean Lyden
1. 12:30 - 12:38
  
  Using the vein as a DETOUR to long, complex, CTOs
2. 12:38 - 12:58
  
  Live case transmission from Leipzig
3. 12:58 - 13:06
  
  Patient selection for the PQ Bypass DETOUR procedure
4. 13:06 - 13:30
  
  Discussion and conclusion
Thursday, January 30th: 13:30 - 15:00, Room 1 - Main Arena 1

Pioneering techniques for “no-option” CLTI patients – deep venous arterialization

Moderator:

Dierk Scheinert, Peter Schneider

Panel:

Roberto Ferraresi, Giacomo Clerici, Michiel Schreve
1. 13:30 - 13:36
  
  Promise and limitations of below-the-ankle revascularisation and pedal loop technique
2. 13:36 - 13:42
  
  The “no-option” CLTI population and prevalence of Small Artery disease
3. 13:42 - 13:48
  
  Surgical, hybrid, and percutaneous DVA – overview of techniques and limitations
4. 13:48 - 13:54
  
  LimFlow PROMISE I study results – the first prospective multi-center trial on DVA
5. 13:54 - 14:00
  
  Ultrasound guided distal AV fistula creations for segmental foot arterialization
6. 14:00 - 14:06
  
  DVA pathophysiology and mechanism of action
7. 14:06 - 14:12
  
  Post-DVA care in a multidisciplinary setting
8. 14:12 - 14:32
  
  Live case transmission from Leipzig
9. 14:32 - 15:00
  
  Discussion and conclusion
Thursday, January 30th: 15:00 - 18:00, Room 1 - Main Arena 1

The last frontiers: Remaining challenges, ongoing controversies, and unmet clinical needs

Moderator:

Jos van den Berg, Prakash Krishnan

Panel:

Torsten Fuß, Thomas Zeller, Hiroshi Ando, Michel Bosiers
1. FOCUS ON ULTRA-LONG LESIONS
2. 15:00 - 15:05
  
  The SUPER B RCT shows VIABAHN® endografts perform as well as open surgical fempop bypass grafts for 2 years
3. 15:05 - 15:10
  
  GORE® VIABAHN® endoprosthesis demonstrates powerful patency in 20+ cm SFA lesions
4. 15:10 - 15:35
  
  Live case transmission from Leipzig
5. 15:35 - 15:40
  
  The ZILVERPASS study: A randomized study comparing ZILVER PTX stenting with BYPASS in femoropopliteal lesions (final 24-month results)
6. FOCUS ON ADVANCED RECANALIZATION TECHNIQUES FOR “NO STENT ZONES”
7. 15:40 - 15:45
  
  Vessel preparation options when stenting is not an option in the popliteal artery
8. 15:45 - 15:50
  
  Utility of the orbital atherectomy system (CSI) in the treatment of no-stenting zones involving isolated lesions of the popliteal artery
9. 15:50 - 15:55
  
  Intravascular lithoplasty in calcified common femoral arteries
10. 15:55 - 16:20
  
  Live case transmission from Münster
11. FIRST CHOICE TREATMENT OF PAOD IN THE COMMON FEMORAL ARTERY
12. 16:20 - 16:25
  
  Pro surgery
13. 16:25 - 16:30
  
  Pro intervention
14. FOCUS ON SEVERE CALCIFIED OCCLUSIONS
15. 16:30 - 16:35
  
  Risk assessment of local lysis therapy in critical limb ischemia: who benefits, who does not?
16. 16:35 - 16:40
  
  My choice of atherectomy system in sever calcification
17. 16:40 - 16:45
  
  Use of Intravascular Lithotripsy in aorto-iliac occlusive disease
18. 16:45 - 16:50
  
  Crack-and-pave techniques: technical tips and follow-up data
19. 16:50 - 17:15
  
  Live case transmission from Leipzig
20. FOCUS ON THROMBUS CONTAINING LESIONS AND IN-STENT-RESTENOSIS
21. 17:15 - 17:20
  
  Treatment approaches for acute limb ischemia
22. 17:20 - 17:25
  
  Aspiration thrombectomy for acute limb ischemia. Is the era of Fogarty balloon over?
23. 17:25 - 17:50
  
  Live case transmission from Abano Terme
24. 17:50 - 17:55
  
  How to treat in-stent-restenosis in the femoropopliteal tract? What does the literature tells us?
25. 17:55 - 18:00
  
  Step by step approach for endovascular salvage of occluded fem-pop bypass
Friday, January 31st: 9:00 - 13:00, Room 1 - Main Arena 1

Critical issues and pioneering solutions in aortic endografting

Moderator:

Giovanni Torsello

Panel:

Martin Malina, Reza Ghotbi, Frank Vermassen, Dittmar Böckler, Armando Lobato

live from Münster:

Martin Austermann

live from Leipzig:

Andrej Schmidt
1. Join us for brunch, served from 08:45am until 11:00am
2. Endovascular management of traumatic aortic injuries: Challenges and solution
3. Successful treatment of post-traumatic arch pseudoaneurysm with fenestrated custom-made TEVAR
4. Endovascular treatment of aortic injury following thoracic spinal surgery: Case report and literature review
5. A new era for CO2 imaging just started
6. Role of cone beam CT in the treatment of ruptured AAA – are we ready to go?
7. Emergency intervention for retrograde Type A acute aortic dissection with PETTICOAT technique
8. Infected TEVAR, FEVAR, and BEVAR – open surgery reloaded

Notice

LINC 2020 programme

LINC 2020 programme

Room 1 - Main Arena 1

Symposium: Stepping forward: Changing the standard of care in lower limb treatments

Welcome

Mimetic stent technology – providing safe, sustained, and optimal care

Live case transmission from Leipzig

Supersub II – preliminary results

STELLA Supera – 12-month results revealed

Live case transmission from Leipzig

Supera VMI-CFA study – 2-year follow-up, ready to change the standard of care?

Discussion and conclusion

Latest insights on safety and efficacy of drug-coated devices

FOCUS ON PACLITAXEL SAFETY

The controversy about Paclitaxel safety – where do we stand? A summary of concerns, available data, and open questions

FIRST TIME DATA RELEASE: In depth independent safety analysis by Syntactx (CRO) of the Lutonix SFA DCB

FIRST TIME DATA RELEASE: Paclitaxel exposure and dosage of drug-coated balloons for the treatment of PAD: Exploring mortality rates by regions around the globe

New long-term information on PTX coated DCB: 5-year results from the AcoArt study

Latest information on long-term efficacy and safety on the Zilver PTX programme

Mortality after use of Paclitaxel-based devices in peripheral arteries: A real-world safety analysis

The presence and the future of drug-coated devices: What to expect in the next 5 years?

Panel discussion

FOCUS ON NEW EFFICACY DATA AND NEW APPROACHES

FIRST TIME DATA RELEASE: COMPARE-RCT of low dose vs. high dose Paclitaxel coated balloons: 1-year results of the full cohort

FIRST TIME DATA RELEASE: 6-month results from Lutonix SFA Japan PMS update

FIRST TIME DATA RELEASE: Illumenate 4-year update

Drug-coated balloon angioplasty of femoropopliteal lesions maintained superiority over standard balloon – 2-year results of the randomized EffPac trial

RANGER II SFA: Randomized trial of RANGER DCB vs. PTA in the SFA

The DCB dose difference: A comparison of drug in tissues of different .018 DCBs

Post-DCB dissection repair: 12-month results from TOBA III

Discussion and conclusion

Symposium: Advanced techniques for the treatment of CLI patients

The role of advanced imaging in CLI

Live case transmission from Leipzig

The role of vessel prep in CLI

Live case transmission from Bergamo

DCB in CLI: Rationale and benefit in current times

Discussion and conclusion

Lunch symposium: Paclitaxel and your practice: Global perspectives

Introduction

How Paclitaxel is perceived in Japan

Impact of society guidelines in my daily practice

Applying the guidelines to my treatment algorithm

Follow the data: Zilver PTX global data analysis

Overcoming the meta-analysis: Moving forward

Summary of symposium, discussion, and debate

Symposium: Optimizing revascularisation in patients with risk factors and complex peripheral arterial lesions

Introduction

Is there a durable treatment option for challenging lesions? the scientific evidence for drug-coated balloons

Anatomically challenging lesion locations: What are my treatment options?

Live case transmission from Bergamo

Opening your BTK treatment options: Unique tools & techniques

Live case transmission from Leipzig

Panel discussion and conclusion

Symposium: AcoArt drug eluting solutions: 5 years safety and effectiveness in FP, latest outcome in BTK

The application of DCB in Type C/D lesion

Redefining DCB in BTK treatment: 12-month outcomes of AcoArt II study

Why DCBs should be first line therapy for most femoropopliteal lesions

DCB in BTK: 12-month results of AcoArt BTK Italy study

Exploring DCB in TAO

Distal embolization after DCB – true or false?

Preliminary experience of using DCB in new indications

Live case transmission from Leipzig

Discussion and conclusion

New stent technologies and advanced concepts for implantable vascular scaffolds

2-year outcomes from the IMPERIAL randomized study of Eluvia and Zilver PTX

BATTLE: A RCT comparing bare metal stent vs. Paclitaxel polymer free eluting stent: 2-year outcomes

ILLUMINA study – 2-year results with a polymer free Sirolimus eluting DES in femoropopliteal arteries

VaibAhn steNt graft placement for superficial femoral artery disease reQUIring endovaScular tHerapy: Vanquish study

Increased outward force of self-expanding BMS in the SFA could be a significant risk factor for a restenosis

Difference in clinical outcomes of low COF stent vs. high COF stent proven in clinical practice

Live case transmission from Berlin

FIRST TIME DATA RELEASE: Final results from the LOCOMOTIVE registry using the VascuFlex Multi-LOC stent system in real-world lesions

TINTIN study: Final 12–month data with the combination of Luminor DCB+SX stent in TASC C and D lesions

A single-center experience with the Tack endovascular system: Real-world tacking above and below-the-knee

Dissecting the TOBA data above and below-the-knee: What it means in practice

Latest updates from the MIMICS clinical programme: Studying BioMimics 3D – The Swirling Flow Stent

1-year results in unselected, real-world patients with the BioMimics 3D Swirling Flow stent in femoropopliteal lesions: The MIMICS-3D Registry

Endoluminal bypass in CLI patient: Long term results